International Journal of Life science and Pharma Reviews (IJLPR)  
  Aim and Scope - To publish peer reviewed review articles in rapidly developing field of Pharma and life sciences  
Pharmaceutical Sciences
Volume 12 Issue 3, May 2022    Pages:86-96
Histomorphological Progression of Diethylnitrosamine (DEN) Induced Hepatocellular Carcinoma Model in Rat  

Kunal Mukherjee, Souvik Biswas, Dipan Roy, Payel Laha, Nabanita Pramanick and Arijit Das
[View PDF]
DOI: 10.22376/ijpbs/lpr.2022.12.3.P86-96
Hepatocellular carcinoma (HCC) commonly known as hepatoma is a frequently occurring liver cancer that occupies 75% of all types of liver cancers. It affects the hepatocellular cells which is the major cell of the liver. Some models can be developed for HCC in rats but it is time-consuming. Nitrosodiethylamine is a very popular carcinogenic drug, very useful to develop experimental animal models. The present study focuses on the establishment of an animal model through a simple approach of experimental protocol along with the duration of the experiment that leads to creating a scope for future studies associated with metastasis as well as anti-metastasis studies. For the present study 2 groups were formed where each group containing 16 rats. Phenobarbital was given for 7 days to each group after diluting with water at a concentration of 0.3g/L before administering the first DEN. The control group received the same number of vehicles for 8 weeks. 50mg/kg of DEN was received intraperitoneally by the animal of the 2nd group twice a week for eight weeks. Bodyweight, the weight of the liver, and all the blood parameters were analysed like alpha-fetoprotein, SGPT, SGOT, and ALP, and a comparison was made with the control group. After evaluating all biological and histological data it can be concluded that the outcome of the present study signifies a simple experimental protocol along with an appropriate experimental duration animal model which leads to help in the study of the mechanism of metastasis and anti-metastasis agent in near future. The current work also represents a straightforward experimental methodology that aids in the investigation of metastatic mechanisms and anti-metastasis agents, with phenobarbital serving as a good promoting agent.
Keywords: Hepatocellular Carcinoma (HCC), DMN, DEN, Phenobarbital, SGPT, SGOT, ALP, Anti-Metastasis Agents
Full HTML:
  1. Jabbour TE, Lagana SM, Lee H. Update on hepatocellular carcinoma: Pathologists' review. World J Gastroenterol. 2019;25(14):1653-1665.
  2. Vyas M, Jain D. An update on subtypes of hepatocellular carcinoma: From morphology to molecular. Indian J Pathol Microbiol. 2021;64(5):112-20.
  3. Ferrante ND, Pillai A, Singal AG. Update on the Diagnosis and Treatment of Hepatocellular Carcinoma. Gastroenterol Hepatol (N Y). 2020;6(10):506-516.
  4. Daniel Motola-Kuba, Daniel Zamora-Valdés, Misael Uribe, Nahum Méndez-Sánchez. ‘Hepatocellular carcinoma. An overview’, Annals of Hepatology. 2005;5(1):16-24.
  5. Waghray A, Murali AR, Menon KVN. Hepatocellular carcinoma: From diagnosis to treatment. World J Hepatol. 2015;7(8):1020-1029.
  6. Rawla P, Sunkara T, Muralidharan P, Raj JP. Update in global trends and aetiology of hepatocellular carcinoma. Contemp Oncol (Pozn). 2018;22(3):141-150.
  7. Ibrahim NE, Aboulthana WM, Sahu RK. Hepatocellular Carcinoma: Causes and Prevention. UK J Pharm Biosci. 2018;6(5):48–55.
  8. Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):1-28.
  10. Balogh J, Victor D, Asham EH, Burroughs SG, Boktour M, Saharia A, Li X, Ghobrial RM, Monsour Jr HP. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016;3:41-53.
  11. Acharya SK. Epidemiology of Hepatocellular Carcinoma in India. J Clin Exp Hepatol. 2014;4(Suppl 3):S27–33.
  12. “Liver cancer overview” Available from: cancer/DS00399/DSECTION=symptoms (Accessed on 29.06.21)
  13. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and Treatment of Hepatocellular Carcinoma. Gastroenterology. 2008;134(6):1752-1763.
  14. Bruix J, Sherman M. Management of Hepatocellular Carcinoma. Hepatology. 2005;42(5):1208-1236.
  15. Vomero MD, Colpo E. Nutritional care of peptic ulcer. ABCD Arq Bras Cir Dig. 2014;27(4):298–302.
  16. Baig B, Halim SA, Farrukh A, Greish Y, Amin A. Current status of nanomaterial-based treatment for hepatocellular carcinoma. Biomed Pharmacother. 2019;116:108852.
  17. Johnson PJ. Non-surgical treatment of hepatocellular carcinoma. HPB (Oxford). 2005;7(1):50–55.
  18. Thandassery RB, Goenka U, Goenka MK. Role of local ablative therapy for hepatocellular carcinoma. J Clin Exp Hepatol. 2014;4(Suppl 3):S104-S111.
  19. Mohamed NK, Hamad MA, Hafez MZ, Wooley KL, Elsabahy M. Nanomedicine in management of hepatocellular carcinoma: Challenges and opportunities. Int J Cancer. 2017;140(7):1475-1484.
  20. Shirakami Y, Gottesman ME, Blaner WS. Diethylnitrosamine-induced hepatocarcinogenesis is suppressed in lecithin:retinol acyltransferase-deficient mice primarily through retinoid actions immediately after carcinogen administration. Carcinogenesis. 2012;33(2):268–274.
  21. Yang CS, Tu YY, Koop DR and Coon MJ. Metabolism of nitrosamines by purified rabbit liver cytochrome P-450 isozymes. Cancer Res 1985;45:1140–1145.
  22. Yoo JS, Guengerich FP and Yang CS. Metabolism of N-nitrosodialkylamines by human liver microsomes. Cancer Res 1988;48: 1499–1504.
  23. Magee PN and Farber E. Toxic liver injury and carcinogenesis. Methylation of rat-liver nucleic acids by dimethylnitrosamine in vivo. Biochem J 1962;83:114–124.
  24. Swann PF and Magee PN. Nitrosamine-induced carcinogenesis. The alklylation of nucleic acids of the rat by N-methyl-N-nitrosourea, dimethylnitrosamine, dimethyl sulphate and methyl methanesulphonate. Biochem J 1968;110:39–47.
  25. George J, Rao KR, Stern R and Chandrakasan G. Dimethylnitrosamine-induced liver injury in rats: the early deposition of collagen. Toxicology 2001;156: 129–138.
  26. Kolaja KL and Klaunig JE. Vitamin E modulation of hepatic focal lesion growth in mice. Toxicol Appl Pharmacol 1997;143:380–387.
  27. Qi Y, Chen X, Chan CY, et al. Two-dimensional differential gel electrophoresis/analysis of diethylnitrosamine induced rat hepatocellular carcinoma. Int J Cancer 2008;122: 2682–2688.
  28. Dapito DH, Mencin A, Gwak GY, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012;21:504–516.
  29. Tolba R, Kraus T, Liedtke C, Schwarz M, Weiskirchen R. Diethylnitrosamine (DEN)-induced carcinogenic liver injury in mice. Lab Anim. 2015;49:59–69.
  30. Bona S, Moreira AJ, Rodrigues GR, Cerski CT, da Silveira TR, Marroni CA, et al. Diethylnitrosamine-induced cirrhosis in Wistar rats: an experimental feasibility study. Protoplasma. 2015;252(3):825–33.
  31. Alves HNC, Da Silva ALM, Olsson IAS, Orden JMG, Antunes LM. Anesthesia with Intraperitoneal Propofol, Medetomidine, and Fentanyl in Rats. J Am Assoc Lab Anim Sci. 2010;49(4):454–9.
  32. Schady DA, Roy A, Finegold MJ. Liver tumors in children with metabolic disorders. Transl Pediatr. 2015;4(4):290–303.
  33. Lang R, Hintner H, Hermann A, Brandstaetter R. Photoperiod modulates melanoma growth in C57BL/6 mice. Exp Dermatol. 2003;12(4):510–3.
  34. Pawar V, Contractor Q. E?Poster Presentations (Oral) | APDW 2019. J Gastroenterol Hepatol. 2019;34(S3):72–582.
  35. “Cat Study - an overview” | ScienceDirect Topics. Available from: (Accessed on 23.08.2021)
  36. Kurma K, Manches O, Chuffart F, Sturm N, Gharzeddine K, Zhang J, et al. DEN-Induced Rat Model Reproduces Key Features of Human Hepatocellular Carcinoma. Cancers 2021, Vol 13, Page 4981. 2021;13(19):4981.
  37. Santos NP, Colaço AA, Oliveira PA. Animal models as a tool in hepatocellular carcinoma research: A Review. Tumor Biol. 2017;39(3):1-20.
  38. De Minicis S, Kisseleva T, Francis H, Baroni GS, Benedetti A, Brenner D, et al. Liver carcinogenesis: Rodent models of hepatocarcinoma and cholangiocarcinoma. Dig Liver Dis. 2013;45(6):450–9.
  39. Lin YL, Li Y. Study on the hepatocellular carcinoma model with metastasis. Genes Dis. 2020;7(3):336–50.
  40. Li Y, Tang ZY, Hou JX. Hepatocellular carcinoma: insight from animal models. Nat Rev Gastroenterol Hepatol. 2011;9(1):32–43.
  41. Zhang HE, Henderson JM, Gorrell MD. Animal models for hepatocellular carcinoma. Biochim Biophys Acta - Mol Basis Dis. 2019;1865(5):993–1002.
  42. Brown ZJ, Heinrich B, Greten TF. Mouse models of hepatocellular carcinoma: an overview and highlights for immunotherapy research. Nat Rev Gastroenterol Hepatol. 2018;15(9):536–54.
  43. Carlessi R, Köhn-Gaone J, Olynyk JK, Tirnitz-Parker JEE. Mouse Models of Hepatocellular Carcinoma. Parker T, Janina EE (1st Edition) Hepatocell Carcinoma. Brisbane (AU), Codon Publications, 2019, pp. 69–94.
  44. Blidisel A, Marcovici I, Coricovac D, Hut F, Dehelean CA, Cretu OM. Experimental models of hepatocellular carcinoma—a preclinical perspective. Cancers (Basel). 2021;13(15):3651.
  45. Liu K, Chen J, McCaughan GW. Animal models for hepatocellular carcinoma arising from alcoholic and metabolic liver diseases. Hepatoma Res. 2020;6:7.
  46. Uehara T, Pogribny IP, Rusyn I. The DEN and CCl4 -Induced Mouse Model of Fibrosis and Inflammation-Associated Hepatocellular Carcinoma. Curr Protoc Pharmacol. 2014;66:14.30.1-14.30.10.
  47. Alkhatib MH, Alnahdi NS, Backer WS. Antitumor Activity, Hematoxicity and Hepatotoxicity of Sorafenib Formulated in a Nanoemulsion Based on the Carrot Seed Oil. Int J Life Sci Pharma Res. 2018;8(1):50–7.
  48. Chavan S, Dias R, Magdum C. Hepatoprotective Effect of Ethanolic Extracts of Allophylus Cobbe (L.) Raeusch leaves against Paracetamol Induced Hepatotoxicity in Albino Wistar Rats. Int J Life Sci Pharma Res. 2021;11(2):107–13.


© 2010-2015 IJLPR rights reserved. Specialized onine journals by ubijournal. Website by Ubitech Solutions